Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 468 of 1,261

  1. US 10435445

    Peptide compound

    Takeda Pharmaceutical Company Limited · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  2. US 10435678

    Modified cascade ribonucleoproteins and uses thereof

    Caribou Biosciences, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  3. US 10435435

    Quinstatin compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  4. US 10435428

    Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

    Theravance Biopharma R&D IP, LLC · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  5. US 10435441

    HTT repressors and uses thereof

    Sangamo Therapeutics, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  6. US 10435438

    Modulation of complement activity

    RA PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  7. US 10435375

    CXCR4 chemokine receptor modulators

    Northwestern University · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  8. US 10435473

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  9. US 10434188

    Hyaluronic acid binding domain-growth factor fusion protein cDNAs and fusion proteins for cartilage matrix preservation and repair

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  10. US 10434175

    Agonist antibodies that bind human CD137 and uses thereof

    Compass Therapeutics LLC · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  11. US 10435355

    Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  12. US 10434181

    Oligomer-containing benzamide-based compounds

    Nektar Therapeutics · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  13. US 10434225

    Para-xylene films and therapeutic uses thereof

    Northwestern University · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  14. US 10434167

    Non-toxic adjuvant formulation comprising a monophosphoryl lipid A (MPLA)-containing liposome composition and a saponin

    The Government of the United States, as represented by the Secretary of the Army · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  15. US 10434134

    Peptide treatment for inflammation and fibrosis

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  16. US 10434131

    Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations

    Nature's Sunshine Products, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  17. US 10434117

    MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes

    Julius-Maximilians-Universitat Wurzburg · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  18. US 10435461

    Therapy for filovirus infection

    The Government of the United States, as represented by the Secretary of the Army · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  19. US 10434100

    Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

    Lixte Biotechnology, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  20. US 10434096

    Tyrosine kinase inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  21. US 10434111

    Compositions and methods for modification of biomolecules

    The Regents of the University of California · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  22. US 10434105

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  23. US 10434063

    Implant compositions for the unidirectional delivery of therapeutic compounds to the brain

    The Board of Regents of the University of Texas System · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

  24. US 10434062

    Compositions and methods of making brittle-matrix particles through blister pack freezing

    The Board of Regents of the University of Texas System · Granted Oct 8, 2019 · Expires Oct 3, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.